Similar articles for PMID: 31092069

Year	Number of Results
1982	1
1991	1
1998	2
1999	1
2000	2
2002	1
2003	1
2004	2
2006	3
2007	2
2008	2
2009	6
2010	3
2011	6
2012	9
2013	6
2014	8
2015	9
2016	10
2017	2
2018	14
2019	10
2020	10
2021	15
2022	14
2023	5
2024	0

1

Androgen receptor modulators: a review of recent patents and reports (2012-2018).

Fujii S, Kagechika H. Fujii S, et al. Expert Opin Ther Pat. 2019 Jun;29(6):439-453. doi: 10.1080/13543776.2019.1618831. Epub 2019 May 19. Expert Opin Ther Pat. 2019. PMID: 31092069 Review.

2

Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.

Isaacsson Velho P, Carducci MA. Isaacsson Velho P, et al. Expert Opin Investig Drugs. 2018 Oct;27(10):811-822. doi: 10.1080/13543784.2018.1513490. Epub 2018 Aug 31. Expert Opin Investig Drugs. 2018. PMID: 30118330 Review.

3

An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.

Mohler ML, Sikdar A, Ponnusamy S, Hwang DJ, He Y, Miller DD, Narayanan R. Mohler ML, et al. Int J Mol Sci. 2021 Feb 20;22(4):2124. doi: 10.3390/ijms22042124. Int J Mol Sci. 2021. PMID: 33672769 Free PMC article. Review.

4

Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor.

Sadar MD. Sadar MD. Expert Opin Drug Discov. 2020 May;15(5):551-560. doi: 10.1080/17460441.2020.1732920. Epub 2020 Feb 26. Expert Opin Drug Discov. 2020. PMID: 32100577 Free PMC article. Review.

5

Peptide antagonist of the androgen receptor.

Gao W. Gao W. Curr Pharm Des. 2010;16(9):1106-13. doi: 10.2174/138161210790963850. Curr Pharm Des. 2010. PMID: 20030610 Review.

6

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hessein M, Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Cherkasov A, Rennie PS. Dalal K, et al. J Biol Chem. 2014 Sep 19;289(38):26417-26429. doi: 10.1074/jbc.M114.553818. Epub 2014 Aug 1. J Biol Chem. 2014. PMID: 25086042 Free PMC article.

7

Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer.

Yeh S, Sampson ER, Lee DK, Kim E, Hsu CL, Chen YL, Chang HC, Altuwaijri S, Huang KE, Chang C. Yeh S, et al. J Formos Med Assoc. 2000 Dec;99(12):885-94. J Formos Med Assoc. 2000. PMID: 11155740 Review.

8

Androgen receptor antagonists for prostate cancer therapy.

Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, Claessens F. Helsen C, et al. Endocr Relat Cancer. 2014 Aug;21(4):T105-18. doi: 10.1530/ERC-13-0545. Epub 2014 Mar 17. Endocr Relat Cancer. 2014. PMID: 24639562 Review.

9

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.

Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F. Crawford ED, et al. J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3. J Urol. 2018. PMID: 29730201 Review.

10

Androgen receptor antagonists: a patent review (2008-2011).

Mohler ML, Coss CC, Duke CB 3rd, Patil SA, Miller DD, Dalton JT. Mohler ML, et al. Expert Opin Ther Pat. 2012 May;22(5):541-65. doi: 10.1517/13543776.2012.682571. Expert Opin Ther Pat. 2012. PMID: 22583332 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

131 results

Results by year